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RESEARCH ARTICLE
Compound heterozygotes and beta-thalassemia:
Top-down mass spectrometry for detection of
hemoglobinopathies
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We have shown previously that liquid extraction surface analysis of dried blood spots coupled to
high resolution top-downMSmay be applied for the diagnosis of hemoglobin (Hb) variants FS,
FAS, FC, FAC, FAD in newborn samples. The objective of the current work was to determine
whether the structural variant HbE, compound heterozygote variants FSC and FSD, and -
thalassemia were amenable to diagnosis by this approach. Anonymized residual neonatal dried
blood spot samples, taken as part of the routine newborn screening program, were analyzed
by liquid extraction surface analysis coupled to high resolution MS/MS. The samples had been
previously screened and were known to be FAE, FSC, FSD, or -thalassemia. Manual analysis
of the mass spectra revealed that, in all cases, the variants may be confirmed. Direct surface
sampling MS should be considered as an alternative to current screening techniques for the
diagnosis of Hb variants.
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1 Introduction
Annually, the UK newborn screening program screens
∼700 000 neonates for five genetic disorders; phenylke-
tonuria, congenital hypothyroidism, cystic fibrosis, medium
chain acyl-CoA dehydrogenase deficiency, and sickle cell dis-
ease (SCD) [1]. SCD has the highest prevalence of all the
disorders screened for by the National Health Service (NHS)
in England with a rate of 1 in 2000 [2]. The term SCD refers to
a set of disorders characterized by the inheritance of the struc-
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tural variant HbS. The variant is formed as a consequence of
a single substitution (GTG for GAG) on the sixth codon of
the -globin chain causing an amino acid substitution of a
glutamic acid to a valine (m −29.9745 Da) at position six
on the -globin chain [3]. When the sickle variant is inher-
ited in a homozygous state (HbSS) it is responsible for sickle
cell anemia, however it is usually phenotypically silent when
inherited in heterozygous form (HbAS).
SCD also includes compound heterozygotes disorders
in which the HbS variant is coinherited with another
hemoglobinopathy, e.g. HbC, HbD Punjab/Los Angeles or
HbE [4]. Clinical significance of these compound heterozy-
gote variants differ. The phenotype for the HbSC variant is
variable: It is generally expressed as a milder form of sickle
cell anemia requiring medical intervention and careful mon-
itoring but in some cases it can be equally/more severe than
HbSS [5]. HbSE syndrome is uncommon and the vast ma-
jority of patients experience no sickle-like symptoms. Rarely,
symptoms may develop requiring medical assistance [6]. The
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compound heterozygotes HbSD Punjab/Los Angeles and the
rare HbSO-Arab phenotypes are severe and have a similar
pathology to HbSS [7].
Thalassemias are hemoglobinopathies characterized by a
reduction in the synthesis of (one of) the globin chains. -
thalassemia is caused by the reduction in the rate of syn-
thesis of the -globin chain leading to an excess accumu-
lation of unbound -globin chains. These unbound globin
chains are released into erythroid precursors in the bone
marrow causing their premature death and therefore unsuc-
cessful erythropoiesis. -thalassemia is classified into three
subtypes. -thalassemia major patients exhibit symptoms of
severe anemia in the first year of life and require regular blood
transfusions in order to survive.-thalassemia intermedia pa-
tients experience milder anemia. Symptoms are usually ap-
parent later in life (between ages 2 and 6 years). Individuals
do not require transfusions to survive however growth and
development is impaired. -thalassemia minor patients are
usually asymptomatic. In -thalassemia major, normal Hb
(HbA) is absent and fetal Hb (HbF) comprises the majority
of Hb in the blood (92–95% total Hb). Less severe cases of
-thalassemia show HbF levels of 70–90% [8, 9] and some
-globin is present.
Neonatal screening for Hb variants allows for early de-
tection, appropriate genetic counseling, and treatment to
reduce deaths from sickle-related complications [10, 11]. In
addition to HbS, the UK NHS newborn screening program
requires that methods used in the screening process must
also be able to reliably detect the structural variants; HbC,
HbD Punjab/Los Angeles, HbE, and HbO-Arab as well as -
thalassemia [12]. Inheritance of the structural variants (with-
out HbS) in either heterozygous or homozygous state is usu-
ally clinically benign.
The current screening protocol uses blood samples col-
lected by midwives via heel prick onto standard NHS dried
blood spot (DBS) cards from neonates between 5 and
8 days old. Small discs (approximately 3 mm in diameter)
are punched out of the DBS and the sample is eluted for ∼30
min [13]. The samples are either analyzed by cation exchange
HPLC (ceHPLC) and/or IEF [14]. Bothmethods are presump-
tive and diagnosis of an Hb variant can only be achieved
by second line testing using DNA analysis (sequencing) or
amino acid analysis (MS) [15].
We have developed a method in which automated direct
surface sampling of theDBS is coupled to top-downMSof the
intact globin chains [16, 17]. The approach circumnavigates
the need for sample preparation and confirms diagnosis in
less than 3 min. In contrast to other MS-based approaches,
there is no requirement for resolubilization of the DBS, use
of tryspin digests [18–20], or HPLC-coupled runs [21]. In our
approach, the DBS is mounted on a platform and a small
volume (a few L) of solvent is spotted onto the sample. After
∼5 s (to allow dissolution of the sample), the solvent con-
taining the sample is reaspirated and injected into the mass
spectrometer via ESI. To diagnose theHb variant, a precursor
ion, corresponding to the intact globin chain, is selected for
fragmentation (MS/MS) within themass spectrometer. Frag-
mentation may be induced by collision induced dissociation
(CID) or electron transfer dissociation (ETD). The result is a
series of sequence fragments from which the presence and
location of an amino acid substitution may be identified un-
ambiguously. We have shown previously that the approach
may be applied to the diagnosis of FS, FAS, FC, FAC, FAD
in newborn samples [16]. In order to consider a suitable tech-
nique for use within the national screening program, the
approach must also be capable of identifying structural vari-
ant HbE, compound heterozygotes, and -thalassemia. Here,
we show that our approach can meet those requirements.
2 Materials and methods
The research was approved by the University of Birmingham
Science, Technology, Engineering and Mathematics Ethical
Review Committee (ERN_11_0722B). Anonymized residual
DBS from normal neonates (FA), heterozygous HbE (FAE),
heterozygous (FAS) sickle trait, sickle cell HbC (FSC), sickle
cell HbD (FSD) neonates, and -thalassemia were supplied
by Birmingham Children’s Hospital in accordance with the
Code of Practice for the Retention and Storage of Residual
Spots [22]. Samples were collected bymidwives 5–8 days after
birth by heel prick onto standard NHS blood spot cards (ID
Biological Systems, Greenville, South Carolina, USA). Fol-
lowing collection, samples were left to dry at room tempera-
ture, and stored in accordance with NHS newborn screening
laboratories standard storage conditions. Prior to the current
work, the samples were screened according to the standard
NHS protocol by ceHPLC and IEF, and the Hb variant status
was known.
2.1 Surface sampling
The DBS was placed onto the Advion Liquid Extraction Sur-
face Analysis (LESA) universal plate adapter (Advion, Ithaca,
NY). An image of the DBS was acquired using an Epson Per-
fection V300 photo scanner. The precise location of the DBS
to be sampled was selected by use of the LESA Points soft-
ware. The universal plate adapter was loaded into the Triversa
Nanomate chip-based nano electrospray device (Advion,
Ithaca, NY), coupled to Thermo Fisher Orbitrap Velos elec-
tron transfer dissociationmass spectrometer (Thermo Fisher
Scientific, Bremen, Germany). Surface sampling was as de-
scribed in [16,17]. Briefly, 7 L of the electrospray/extraction
solution (methanol (J.T. Baker, Denveter, The Netherlands)
and water (J.T Baker; 48.5:48.5), with 3% formic acid
(Sigma-Aldrich Company, Dorset, UK) was aspirated from
the solvent well. Six microliters of the solution was dispensed
onto the DBS forming a sample surface-to-tip liquid micro-
junction. The liquid microjunction was maintained for 5 s,
before 5 L was reaspirated and electrosprayed into the mass
spectrometer.
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2.2 MS
The sample was introduced at flow rate of ∼80 nL/min, with
a gas pressure of 0.5 psi, tip voltage of 1.75 kV, and capillary
temperature of 250C. MS data were collected in full-scan
mode (m/z 600–2000) and SIM mode (m/z 1055–1090) at a
resolution of 100 000 at m/z 400 in the orbitrap. Each scan
comprises 30 coadded microscans. Mass spectra shown com-
prise approximately five scans. Automatic gain control target
was 1 × 106 with a maximum fill time of 2 s. CID was per-
formed in the ion trap (isolation width of 10 Th) and the
fragment ions detected in the orbitrap with a resolution of
100 000 at m/z 400. CID experiments were performed with
helium gas at a normalized collision energy of 30%. Each
CID scan comprises 30 coadded microscans. MS/MS spec-
tra shown (m/z 290–2000) comprise five coadded scans. Data
were analyzed using Xcalibur 2.10 software (Thermo Fisher
Scientific) where the Xtract program was used to calculate
monoisotopic masses (44% fit factor, 25% remainder). All
spectra were manually analyzed.
3 Results
3.1 HbE
The HbE variant occurs at position 26 on the -globin chain
where a glutamic acid is substituted for a lysine, resulting in
a mass shift of m –0.9476 Da [23]. Figure 1a shows a com-
parison of SIM-mode mass spectra from a normal (FA) and
FAE neonatal sample. The spectra show peaks corresponding
to the isotopic distributions of multiply charged [M+14H]14+
ions of the -chain (MWcalc 15117.8924), [M+15H]15+ ions
of the -chain (MWcalc 15858.2570), and [M+15H]15+ ions
of the -chains (from HbF; A MWcalc 15986.2626 and G
MWcalc 16000.2782). The resolving power of the orbitrapmass
spectrometer used in the work is capable of differentiating
between isotopic species containing 13C and therefore it is
possible to determine the monoisotopic mass experimentally
by use of deconvolution software such as Xtract. (Mass spec-
trometers with low resolving powers are only capable of de-
termining average masses.) Nevertheless, it is not possible to
unambiguously determine the presence of the HbE variant
because the small mass shift (m −0.9476 Da) of the vari-
ant means that isotope peaks from the intact variant globin
overlap with those from the intact -globin. Using a broad
isolation window (10 Th), it is possible to select both precur-
sor ion types and subject them to simultaneous fragmenta-
tion. This step can be achieved without a priori knowledge
of the presence of the variant and so could be easily incorpo-
rated into a screening protocol. The resulting fragmentation
allowed unambiguous diagnosis of the phenotype. A peak
corresponding to normal b243+ fragment ions was observed
(m/zmeas 852.1195) verifying that theHb variant is not present
before position 25 on the globin chain. Figure 1b shows the
regions of the MS/MS spectra containing the b324+ fragment
Figure 1. (A) SIM mass spectra of FA (top) and FAE (bottom).
Expanded m/z region showing peaks corresponding to the iso-
topic distributions of (B) b324+ fragments observed following CID
of -chain ions (m/zcalc 843.2096; top) and variant HbE (m/zcalc
842.9727) (bottom), and (C) b354+ fragments following CID of -
chain ions (m/zcalc 933.5096; top) and HbE variant ions (m/zcalc
933.2727; bottom). (D) CID sequence coverage of heterozygous
FAE.
ion from the FA and FAE samples. The peak atm/z 842.9724
in the FAE MS/MS spectrum (and absent in the FA spec-
trum) has a mass shift of −0.9476 Da when compared with
the fragment from the FA sample, i.e. substitution of glu-
tamic acid for lysine. The only glutamic acid residue between
positions 24 and 32 on the -globin chain is located at po-
sition 26 therefore the HbE variant can be confirmed. The
presence of b344+, b353+, and b354+ fragment ions with mass
shifts of −0.9476 Da, and of y11110+, y11111+,y11112+, y11210+,
and y11212+ fragment ions at the expected masses all confirm
the presence of the HbE variant. The region of themass spec-
trum containing the b354+ fragment ions is shown in Fig. 1c.
Full details of the observed fragments are given in Support-
ing Information Table 1. It is also possible to determine from
this fragment that the variant is present in the heterozygous
state. Two sets of overlapping isotope peaks can be clearly
distinguished (although not baseline resolved). In England,
C© 2014 The Authors. PROTEOMICS published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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FAE carrier rate has been reported as 1 in 639 neonates [24].
CID resulted in a total sequence coverage of 43%, i.e. frag-
ments resulting from cleavage of 63/145 individual peptide
bonds were observed. The sequence coverage, i.e. the experi-
mentally observed fragment ions, is shown in Fig. 1d, but it
should be noted that, as the sample is heterozygous and both
normal and variant globin chains were selected for fragmen-
tation, the sequence coverage has contributions from both.
Thirteen of the fragments are unique to HbE, whereas the
remainder are common to both.
3.2 Compound heterozygotes
3.2.1 HbSC
HbSC is a compound heterozygote composed of two normal
-chains and two variant -chains. One abnormal chain is
caused by a substitution of a Glu→Lys at position 6 (HbC)
on the -chain, resulting in a mass shift of –0.9476 Da, and
the other abnormal chain is caused by the HbS variant, a
substitution also at position 6 on the -chain, Glu→Val (m
+ 29.9745 Da). Figure 2a shows SIM-mode mass spectra
of heterozygous sickle (FAS) and compound heterozygous
FSC samples. As we have described previously, it is possi-
ble to determine the presence of the sickle variant and its
nature (homo- or heterozygous) in this mode [16]. Neverthe-
less, there exists the possibility of misdiagnosis of compound
heterozygotes—the mass spectra in Fig. 2a top (FAS) and
bottom (FSC) appear identical. That is significant because
whereas FAS is generally benign, the clinical severity of FSC
is similar to that of homozygous sickle. FSC has a prevalence
rate of 1 in 7174 in England [24]. For both the FAS and FSC
sample, ions centered at m/z 1056 were isolated and sub-
jected to CID. The isolation width was 10 Th meaning that
both HbS and -chain ions (in the case of FAS) or both HbS
and HbC ions (in the case of FSC) were selected for fragmen-
tation. The protein sequence coverage (i.e. the experimen-
tally observed fragment ions) obtained for the HbC variant
chain is 24% and is shown in Fig. 2b. Full details of the frag-
ment ion assignments are given in Supporting Information
Table 2. Figure 2c shows the expandedm/z region containing
the b474+ fragments of the FAS and FSC variants. The peaks at
m/z 1300.4444 and 1307.6914 in Fig. 2c, bottom, confirm the
presence of bothHbS andHbC, i.e. the sample is a compound
heterozygote FSC. Figure 2d and e shows further examples
that confirm the presence of the HbC variant.
3.2.2 HbSD
HbSD is another compound heterozygote where two variant
chains are inherited: one HbS chain (substitution also at po-
sition 6 of the -chain, Glu→Val (+29.974)) and one HbD
chain (Glu→Gln substitution at position 121 of the -chain,
m −0.9840 Da). The SIM-mode mass spectra of FAS and
FSD samples are shown in Fig. 3a look identical. This is be-
Figure 2. (A) SIM mass spectra of heterozygous FAS (top) and
compound heterozygous FSC (bottom). (B) CID sequence cover-
age of heterozygous FSC (variant HbC ions only). (C) Expanded
m/z region showing the b474+ fragments observed following
CID of the sickle ions (m/zcalc 1300.4330), -chain ions (m/zcalc
1307.9266), and HbC variant ions (m/zcalc 1307.6897). (D) Ex-
panded m/z region showing b223+ fragments for the -chain ions
(m/zcalc 802.0884; top) and HbC variant ions (m/zcalc 801.7726; bot-
tom). (E) Expanded m/z region showing b142+ fragments for the
-chain ions (m/zcalc 738.9065; top) and HbC variant ions (m/zcalc
738.4327; bottom).
cause the normal -globin chain differs in mass from the
variant D Punjab/Los Angeles chain by only 0.9840 Da. The
presence of the sickle variant in both samples is clear in SIM
mode. CID fragmentation is required to differentiate between
clinically benign FAS and the severe medical disorder FSD.
The protein sequence coverage (i.e. the experimentally ob-
served fragment ions) obtained for the HbD variant chain is
15% and is shown in Fig. 3b. Full details of the fragment ion
assignments are given in Supporting Information Table 3.
FSD is unambiguously diagnosed as the fragment ion y234+
(m/zmeas 608.8415) is normal but the next fragment observed,
y324+, is present at m/zmeas 872.4143 corresponding to a vari-
ant with a mass shift of −0.9840 Da (Glu→Gln), Fig. 3c.
C© 2014 The Authors. PROTEOMICS published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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Figure 3. (A) SIM mass spectra of normal neonate Hb heterozy-
gous and homozygous FAS (top) and FSD (bottom). (B) CID se-
quence coverage of heterozygous FSD (variant HbD ions only).
(C) Expanded m/z region showing the y324+ fragments observed
following CID of the -chain ions (m/zcalc 1307.9266; top) in the
FAS sample and HbD variant ions (m/zcalc 872.2140; bottom) in
the FSD sample. (D) Expandedm/z region showing both the b333+
fragments observed following CID of the HbS variant ions (m/zcalc
1146.9751) and the y969+ fragment ions of the -chain ions (m/zcalc
1148.6083) and HbD variant ions (m/zcalc 1148.4982).
The only glutamic acid residue present between y23 and y32 is
at position 121. This variant is therefore confirmed as HbD
Punjab/Los Angeles (121 Glu→Gln m −0.9840 Da), and
the individual is diagnosed as compoundheterozygoteHbSD.
3.2.3 -Thalassemia
Five different -thalassemia DBS samples were investigated
in this study. The variant DBS underwent standard hospital
screening (ceHPLC) and the samples were diagnosed as be-
ing -thalassemia major, i.e. no -chain is present. All the
samples were then analyzed by use of the LESA protocol. In
full MS mode, no peaks corresponding to -globin chains
were observed in any of the five -thalassemia samples.
Figure 4 shows a representative SIM-mode mass spectrum
(m/z range 1055–1090) for a -thalassemia variant. The spec-
trum was deconvoluted by use of the Xtract software to deter-
mine the monoisotopic masses of the measured ions. The
measured MW of the -chain from the spectrum shown
in Fig. 4 was 15 117.8346 Da (m −3.8 ppm), G-chain
15 986.1963 Da (m−4.2 ppm), and for the A is 16 000.2017
(m −4.8 ppm). The -globin chain was absent. Supporting
Information Fig. 1 shows SIM-mode mass spectrum (m/z
range 1055–1090) of all five -thalassemia samples. All sam-
ples were analyzed from full term neonates so the absence of
 -globin cannot be explained by neonatal prematurity (pro-
duction of -chain not yet switched on). The absence of the
-globin chain in the samples must therefore be explained by
the presence of -thalassemia major. Clinically symptomatic
-thalassemia has an incidence of about 1 in 10 000 within
the European Union [8].
4 Discussion
The UK NHS newborn screening program requires that
the following Hb variants must be detected: HbSS,
HbS/-thalassemia, HbSC, HbSD, HbSE, HbSO-Arab, and
HbS/HPFH (hereditary persistence of HbF). Direct surface
sampling of DBS coupled to high resolution top-downMS al-
lows for the rapid and unequivocal diagnosis of Hb variants.
We have shown previously that our approach is suitable for
screening for variants HbS (homo- and heterozygous), HbC
(homo- and heterozygous), and HbD (heterozygous). Here,
we show that the approach is also suitable for the structural
variant HbE. This result is perhaps not surprising as the
HbE variant is the result of a Glu→Lys substitution, as is
the HbC variant. More importantly, we have shown that the
approach is suitable for the diagnosis of compound heterozy-
gotes (HbSC and HbSD) and that this diagnosis requires a
single MS/MS analysis. That is, both the HbS and other vari-
ant are selected and fragmented in a single event. Given the
identical mass shift of HbC and HbE, and the fact that (nor-
mal) heterozygous HbE can be determined, it is reasonable
to predict that the compound heterozygous HbSE can be di-
agnosed by this approach. The HbO-Arab variant is rare [7]
and no samples were available for analysis during this study.
(Variants FSE, FSO-Arab, and other sickle compound het-
erozygotes including FSD have a combined prevalence of
rate of 1 in 24 871 [24]). HbO-Arab occurs at position 121 on
the -chain, i.e. at the same position as the HbD Punjab/Los
Angeles variant, and is the result of a substitution of glutamic
acid for lysine, i.e. an identical mass shift to variants HbC and
HbE.We have clearly shown that HbC,HbD, andHbE can all
be diagnosed by our direct surface sampling top-downMS ap-
proach, and therefore fully anticipate being able to diagnose
the Hb O-Arab variant as well.
We have also shown that the method is capable of
confirming -thalassemia major, a clinically significant
C© 2014 The Authors. PROTEOMICS published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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Figure 4. SIM-mode mass
spectrum of a neonatal -
thalassemia sample.
hemoglobinopathy, which should be detected in newborn
screening. Nevertheless, caution is advised: the absence of
a mass spectral feature cannot automatically be interpreted
as evidence of absence of the analyte. For -thalassemia ma-
jor screening, the method would be suitable either as first
line testing with subsequent diagnosis via DNA analysis, or
as a second line test. It is also worth noting, that in neona-
tal samples, the same results would be expected for HbSS,
HbS/-thalassemia, and HbS/HPFH, i.e. peaks correspond-
ing to HbS, -chains and -chains and an absence of peaks
corresponding to -chain.
Results from this study show the method can be realis-
tically considered as an alternative to the current protocol.
The use of MS as a first line screening method would speed
up definitive diagnosis of clinically significant Hb variants,
which can currently take several weeks. The direct surface
sampling aspect of this method is advantageous in the clini-
cal setting as it offers minimal sample handling and does not
require any sample preparation. The process has the potential
to become fully automated with the development of a device
that could automatically load and remove hundreds of DBS
cards into and out of the Triversa Nanomate ESI source for
the surface sampling. The method could also be easily trans-
ferred for use in antenatal hemoglobinopathy screening.
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